Abstract: Myelodysplastic syndromes (MDS) are heterogeneous clonal stem cell disorders characterised not only by peripheral cytopenia and bone marrow hyperplasia but also by karyotype. The course of disease, clinical outcome and response to treatment. Cytogenetic categories is a pattern typing the intrinsical features of MDS. It is suggested here that investigating biological characters and group treatment in MDS based on cytogenetic categories may enhance the therapeutic effect and bring benefit to MDS patients.